Building Breakthroughs Together
Our trusted partners drive innovation and amplify our impact. Together, we shape the future of cancer treatment.
Our Valued Partners in Innovation
Agoranov
PepKon is proud to be part of the Agoranov incubator, which provides essential support for our growth and development. Through this program, we gain access to strategic mentorship, networking opportunities, and a dynamic community of innovators, fostering collaboration and inspiring new ideas.
Gustave Roussy
PepKon collaborates with the Gustave Roussy Institute to develop peptide therapies targeting various cancer cell lines with high unmet medical needs. This partnership aims to advance innovative treatments for challenging cancer types, leveraging Gustave Roussy's expertise in oncology research.
Catapult
PepKon was also selected for the prestigious EIT Health Catapult program, which offers access to an extensive international network and specialized mentorship. This opportunity will accelerate our growth and amplify our capacity to bring innovative cancer therapies to market.
BPI France
PepKon has received substantial support from Bpifrance, including the OC French Tech Seed, Innov’up Leader PIA, and Deeptech Development programs, and was honored as a laureate of the prestigious I-Lab competition.
CALYM
CALYM provides Pepkon with its expertise in translational and clinical research, as well as access to advanced technological platforms and preclinical models. This collaboration accelerates the development and validation of therapeutic peptides for potential indications in lymphomas.
VCLS
Voisin Consulting Life Sciences (VCLS) supports Pepkon by providing a tailored regulatory strategy and roadmap for the EU. This includes guidance on compliance, regulatory submissions, and market entry requirements, ensuring the efficient development and approval of therapeutic peptides.
ICOSA
ICOSA supports Pepkon by providing strategic expertise in intellectual property management. This ensures robust safeguarding of Pepkon's innovations in therapeutic peptides, reinforcing their competitive edge and supporting efficient development strategies in oncology.